Navigation Links
Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
Date:9/17/2012

LA JOLLA, Calif., Sept. 17, 2012 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic-driven solutions to solve a range of global challenges, today announced they have purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to key synthetic genomic technologies. All related know-how, equipment and technical support for implementation, were also purchased.

This newly acquired SGI technology includes methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA.  Together, these technologies have the potential to drastically reduce the cost of DNA synthesis, a technical problem the synthetic biology community has faced since the first synthetic gene was produced forty years ago.

"The intellectual property from Febit will strengthen and accelerate SGI's ongoing development and commercialization of a variety of products including algae-based food and nutritional products, biofuels, biochemicals, synthetic vaccines and clean water," said J. Craig Venter, Ph.D., Founder and CEO, SGI. "The ability to construct accurate and inexpensive DNA, together with our current proprietary DNA assembly and genome transplantation methodologies, enable enhanced capacity to synthesize DNA and reprogram cells at a larger scale than what is currently achievable."

The newly acquired SGI patent families include seven issued United States and European patents covering methods to produce polymers, specifically double stranded, synthetic nucleic acids from a variety of oligonucleotides on a solid support; and methods for retrieving sequence verified synthetic nucleic acids following assembly on solid supports.  These methods can be used to quickly synthesize genetic components in parallel, and then selectively assemble the components having the perfect sequence into double stranded genes and larger DNA constructs with minimal errors.

About Synthetic Genomics Inc.

SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key research and business programs including: developing algae biofuels in alliance with Exxon Mobil Research and Engineering Company, microbial-enhanced hydrocarbon recovery and conversion through an agreement with BP, new and improved food and nutritional products, and clean water technologies. SGI is also involved in synthetically derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a company co-founded with the J. Craig Venter Institute; and to developing sustainable crops and agricultural products through Agradis Inc., a company co-founded with Plenus S.A. de C.V. For more information go to: www.syntheticgenomics.com.

Media Contact: Heather Kowalski, 858-361-0466, hkowalski@syntheticgenomics.com


'/>"/>
SOURCE Synthetic Genomics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
2. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
3. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
4. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
5. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
6. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Adeona Becomes Synthetic Biologics, Inc.
9. Startling results in synthetic chemistry presented in Nature Chemistry
10. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
11. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):